A post-hoc analysis of the phase 3b JUMP trial found that ruxolitinib plus anemia supportive care maintained efficacy and reduced transfusion needs in patients with myelofibrosis.

Cellarity has dosed the first subject in a Phase I study of oral medication, CLY-124, to treat sickle cell disease (SCD).

A post-hoc analysis of the phase 3b JUMP trial assessed outcomes in patients with myelofibrosis and baseline anemia who were treated with ruxolitinib alongside anemia-supportive therapies, according ...

Clinical assessment of a subject with IDA may reveal manifestations of anaemia (eg, breathlessness, fatigue, heart failure) and on occasion more specifically of iron deficiency (such as angular ...

A new survey of 500 UK adults, conducted by LloydsPharmacy Online Doctor, found that only 25% of people would know the common ...

Cellarity, a biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced that the first subject has been dosed in a Phase 1 ...

In her presentation at AANP 2025, Dr Haylei Lorca includes case studies of 3 patients who present with atypical psychiatric symptoms.

During a live event, Thomas LeBlanc, MD, MA, discussed the outcomes of the COMMANDS trial of luspatercept in myelodysplastic ...

RELATED: Five Iron-Rich Foods to Give Anemia Eviction Notice. Combating Anemia Symptoms. The following are tips for combating those unpleasant anemia symptoms this fall: 1. Dress warmly. As the ...

Sickle cell disease refers to a group of inherited blood disorders with symptoms like anaemia and blocked blood vessels. About 80% of the world's sickle cell disease cases occur in sub-Saharan Africa.

Panelists discuss how to select among the four available JAK inhibitors (Ruxolitinib, Fedratinib, Pacritinib, and Momelotinib) based on patient-specific factors such as anemia, thrombocytopenia, and ...